Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study

JAMA Oncology

Volumn 3, Issue 9, 2017, Pages

  Powles, Thomas ^a   O'Donnell, Peter H ^b   Massard, Christophe ^c   Arkenau, Hendrik Tobias ^d   Friedlander, Terence W ^e   Hoimes, Christopher J ^f   Lee, Jae Lyun ^g   Ong, Michael ^h   Sridhar, Srikala S ⁱ   Vogelzang, Nicholas J ^j   Fishman, Mayer N ^k   Zhang, Jingsong ^k   Srinivas, Sandy ^l   Parikh, Jigar ^m   Antal, Joyce ⁿ   Jin, Xiaoping ⁿ   Gupta, Ashok K ⁿ   Ben, Yong ^o   Hahn, Noah M ^p  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CHICAGO   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g University of Ulsan College of Medicine   (South Korea)

^h OTTAWA REGIONAL CANCER CENTRE   (Canada)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j Department of Hematology Oncology   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^l STANFORD UNIVERSITY   (United States)

^m MEDICAL COLLEGE OF GEORGIA   (United States)

ⁿ MEDIMMUNE   (United States)

^o ASTRAZENECA   (United Kingdom)

^p JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DURVALUMAB; GAMMA GLUTAMYLTRANSFERASE; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; ADVERSE EVENT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIAL FIBRILLATION; AUTOIMMUNE HEPATITIS; BLADDER METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERTENSION; HYPERTRANSAMINASEMIA; INFUSION RELATED REACTION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR FLARE; ABDOMINAL NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; RETREATMENT; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; SURVIVAL RATE;

EID: 85030424068     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.2411     Document Type: Article

References (17)

1. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454-4461.
2. Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26(4):812-817.
3. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847-856.
4. Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468(5):511-525.
5. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974-1982.
6. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-477.
7. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590-1598.
8. Bellmunt J, de Wit R, Vaughn DJ, et al; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-1026.
9. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(9):4275-4280.
10. Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212-220.
11. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031): 1909-1920.
12. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528): 558-562.
13. Apolo AB, Infante JR, Hamid O, et al. Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. J Clin Oncol. 2016;34(suppl 2S): abstr 367.
14. Loriot Y, Rosenberg JE, Powles TB, et al. Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the Ph II IMvigor210 study. Ann Oncol. 2016;27(suppl 6): abstr 783P.
15. Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052-1062.
16. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26): 3119-3125.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.